1. Cost analysis of re-exploration for bleeding after coronary artery bypass graft surgery 
U. Alström, L.-Å. Levin, E. Ståhle, R. Svedjeholm, Ö. Friberg 
British Journal of Anaesthesia 
Volume 108, Issue 2, Pages (February 2012)
DOI: /bja/aer391
Copyright © 2012 The Author(s) Terms and Conditions

2. Fig 1
Cost of prophylactic haemostatic treatment, per patient, where the cost is exactly balanced by a reduction in costs for bleeding-related re-explorations at 25%, 50%, 75%, and 100% efficacy of the prophylactic drug. Dotted lines provide examples for patients with and without pre-CABG exposure to clopidogrel (re-exploration frequency 5.1% for clopidogrel-treated patients and 2.5% for patients not receiving clopidogrel), assuming 100% efficacy of the prophylaxis.
British Journal of Anaesthesia  , DOI: ( /bja/aer391)
Copyright © 2012 The Author(s) Terms and Conditions

3. Fig 2
Net cost per patient for prophylaxis with rFVIIa resulting in prevention of re-exploration, depending on the expected frequency of re-exploration without prophylactic treatment in that population and for various efficacies of prophylactic treatment (25%, 50%, 75%, and 100% efficacy). Calculations were made for a 70 kg person receiving 40 μg kg−1 rFVIIa.
British Journal of Anaesthesia  , DOI: ( /bja/aer391)
Copyright © 2012 The Author(s) Terms and Conditions